Noticias de PRLD_US

Noticias del mercado

Últimas noticias sobre PRLD_US — 60 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: PRLD_US ✕ 60 resultados
20/04/2026 PRLD_US — GuruFocus ES ← EN
Prelude Therapeutics (PRLD) revela datos preclínicos prometedores

Prelude Therapeutics (PRLD) Unveils Promising Preclinical Data f

20/04/2026 PRLD_US — GuruFocus ES ← EN
Prelude Therapeutics (PRLD) lanza oferta pública de 90 millones de dólares con S

Prelude Therapeutics (PRLD) Launches $90M Public Offering with S

20/04/2026 PRLD_US — GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S
20/04/2026 PRLD_US — GuruFocus
Prelude Therapeutics (PRLD) Launches $90M Public Offering with S
20/04/2026 PRLD_US — ChartMill
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
20/04/2026 PRLD_US — Minichart
Prelude Therapeutics Unveils Promising Preclinical Data for First-in-Class Oral KAT6A Degrader PRT13722 in HR+/HER2- Breast Cancer at AACR 2026 12
20/04/2026 PRLD_US — Yahoo Finance
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
20/04/2026 PRLD_US — ChartMill
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
15/04/2026 PRLD_US — GuruFocus ES ← EN
Prelude Therapeutics (PRLD) nombra nuevo director médico
15/04/2026 PRLD_US — GuruFocus
Prelude Therapeutics (PRLD) Appoints New Chief Medical Officer
15/04/2026 PRLD_US — Investing.com Canada
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com
15/04/2026 PRLD_US — Yahoo Finance
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15/04/2026 PRLD_US — Investing.com
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com
15/04/2026 PRLD_US — Stock Titan
New CMO joins Prelude Therapeutics (NASDAQ: PRLD) as pipeline advances
15/04/2026 PRLD_US — Investing.com
Prelude Therapeutics names Charles Morris as chief medical officer
15/04/2026 PRLD_US — ChartMill
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
15/04/2026 PRLD_US — Minichart
Prelude Therapeutics Appoints Dr. Charles Morris as Chief Medical Officer to Advance Precision Oncology Pipeline
15/04/2026 PRLD_US — Investing.com India
Prelude Therapeutics names Charles Morris as chief medical officer By Investing.com
21/03/2026 PRLD_US — Stock Titan ES ← EN
Si invirtió $ 1,000 en Prelude Therapeutics Inc (PRLD)
17/03/2026 PRLD_US — Yahoo Finance
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting

Página 3 de 3

keyboard_arrow_up